Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (Q28258863)

Expert Opinion on Investigational Drugs

Europe PubMed Central

title

Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting (English)

0 references

0 references

Rudolph M Navari

1

0 references

language of work or name

English

0 references

publication date

December 2007

0 references

published in

0 references

volume

16

0 references

issue

12

0 references

page(s)

1977-85

0 references

1 reference

https://api.crossref.org/works/10.1517/13543784.16.12.1977

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III ran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

The pathophysiology of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Drug treatment of chemotherapy-induced delayed emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Potential of substance P antagonists as antiemetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977

Emerging drugs for chemotherapy-induced emesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.16.12.1977